NCT07843862Not yet recruitingPhase 2
A Study of HRS-4729 Injection in Participants With Type 2 Diabetes
A Phase II, Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group Clinical Trial Evaluating the Efficacy and Safety of HRS-4729 Injection in Participants With Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 28 Sept 2026
Brief summary (registry, in English)
The main purpose of this study is to evaluate the efficacy and safety of HRS-4729 Injection in participants with type 2 diabetes who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- First submitted
- 22 Sept 2026
- Start date
- Oct 2026
- Primary completion date
- Apr 2027
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Diseases
- Type 2 diabetes
- NCT number
- NCT07843862
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 240
- From Oct 2026 to the primary completion date, Apr 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of any condition affecting gastric emptying, long-term use of medications directly affecting gastrointestinal motility, severe gastrointestinal disease, or prior gastrointestinal surgery
Other illness
- Have uncontrolled hypertension
- Have Type 1 Diabetes, or specific types of diabetes
- History of acute diabetic complications or severe hypoglycemic events
- History of severe chronic diabetic complications, or non-proliferative diabetic retinopathy requiring treatment
- History or known history of acute or chronic pancreatitis, or pancreatic injury
- History or known history of acute cholecystitis, or symptomatic/treatment-requiring gallbladder disease
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2)
Who the study is looking for
- Have Type 2 Diabetes
- Treated with diet and exercise alone or with a stable dose of metformin
- Have an HbA1c value at screening of ≥7.5% and ≤10.5%
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tianjin Medical University Chu Hsien-I Memorial Hospital Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
| Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.